Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.8%

7 terminated/withdrawn out of 145 trials

Success Rate

72.0%

-14.5% vs industry average

Late-Stage Pipeline

14%

20 trials in Phase 3/4

Results Transparency

0 of 18 completed trials have results

Key Signals

46 recruiting6 withdrawn

Enrollment Performance

Analytics

N/A

35(38.0%)

Phase 2

23(25.0%)

Phase 4

12(13.0%)

Phase 1

11(12.0%)

Phase 3

8(8.7%)

Early Phase 1

3(3.3%)

92Total

N/A(35)

Phase 2(23)

Phase 4(12)

Phase 1(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (145)

Showing 20 of 145 trials

NCT05453721Not ApplicableCompleted

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529）

Role: collaborator

NCT07532122Completed

Postoperative Anxiety and Depression Among Chinese Elderly Patients

Role: collaborator

NCT07556653Early Phase 1Not Yet Recruiting

Allogeneic WTX-212C in Advanced Solid Tumors

Role: lead

NCT07554898Phase 2Recruiting

Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma: A Prospective, Multicenter Phase Ⅱ Study

Role: collaborator

NCT07550972Phase 2Enrolling By Invitation

Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

Role: lead

NCT06464965Phase 1Completed

Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer

Role: lead

NCT06968936Not ApplicableRecruiting

Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy

Role: collaborator

NCT04866667Completed

Observational Study of ASCVD Risks of Type 2 Diabetes in East China